BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37253112)

  • 21. Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variants.
    Huang H; Hu C; Na J; Hart SN; Gnanaolivu RD; Abozaid M; Rao T; Tecleab YA; Pesaran T; Lyra PCM; Karam R; Yadav S; Domchek SM; de la Hoya M; Robson M; Mehine M; Bandlamudi C; Mandelker D; Monteiro ANA; Boddicker N; Chen W; Richardson ME; Couch FJ
    bioRxiv; 2023 Dec; ():. PubMed ID: 38168194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer.
    Neidhardt G; Becker A; Hauke J; Horváth J; Bogdanova Markov N; Heilmann-Heimbach S; Hellebrand H; Thiele H; Altmüller J; Nürnberg P; Meindl A; Rhiem K; Blümcke B; Wappenschmidt B; Schmutzler RK; Hahnen E
    Eur J Cancer Prev; 2017 Mar; 26(2):165-169. PubMed ID: 27622768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families.
    Romero A; Pérez-Segura P; Tosar A; García-Saenz JA; Díaz-Rubio E; Caldés T; de la Hoya M
    Breast Cancer Res Treat; 2011 Oct; 129(3):939-46. PubMed ID: 21537932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.
    Zheng Y; Zhang J; Hope K; Niu Q; Huo D; Olopade OI
    Breast Cancer Res Treat; 2010 Dec; 124(3):857-61. PubMed ID: 20697805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.
    Li N; McInerny S; Zethoven M; Cheasley D; Lim BWX; Rowley SM; Devereux L; Grewal N; Ahmadloo S; Byrne D; Lee JEA; Li J; Fox SB; John T; Antill Y; Gorringe KL; James PA; Campbell IG
    J Natl Cancer Inst; 2019 Dec; 111(12):1332-1338. PubMed ID: 30949688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline mutations in RAD51C in Jewish high cancer risk families.
    Kushnir A; Laitman Y; Shimon SP; Berger R; Friedman E
    Breast Cancer Res Treat; 2012 Dec; 136(3):869-74. PubMed ID: 23117857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
    Sullivan MR; Prakash R; Rawal Y; Wang W; Sung P; Radke MR; Kaufmann SH; Swisher EM; Bernstein KA; Jasin M
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain).
    Sánchez-Bermúdez AI; Sarabia-Meseguer MD; García-Aliaga Á; Marín-Vera M; Macías-Cerrolaza JA; Henaréjos PS; Guardiola-Castillo V; Peña FA; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Eur J Med Genet; 2018 Jun; 61(6):355-361. PubMed ID: 29409816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional analysis of germline RAD51C missense variants highlight the role of RAD51C in replication fork protection.
    Kolinjivadi AM; Chong ST; Choudhary R; Sankar H; Chew EL; Yeo C; Chan SH; Ngeow J
    Hum Mol Genet; 2023 Apr; 32(8):1401-1409. PubMed ID: 36562461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
    Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
    J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.
    Pelttari LM; Shimelis H; Toiminen H; Kvist A; Törngren T; Borg Å; Blomqvist C; Bützow R; Couch F; Aittomäki K; Nevanlinna H
    Clin Genet; 2018 Mar; 93(3):595-602. PubMed ID: 28802053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A decade of RAD51C and RAD51D germline variants in cancer.
    Boni J; Idani A; Roca C; Feliubadaló L; Tomiak E; Weber E; Foulkes WD; Orthwein A; El Haffaf Z; Lazaro C; Rivera B
    Hum Mutat; 2022 Mar; 43(3):285-298. PubMed ID: 34923718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare
    Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
    Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Boonen RACM; Wiegant WW; Celosse N; Vroling B; Heijl S; Kote-Jarai Z; Mijuskovic M; Cristea S; Solleveld-Westerink N; van Wezel T; Beerenwinkel N; Eeles R; Devilee P; Vreeswijk MPG; Marra G; van Attikum H
    Cancer Res; 2022 Feb; 82(4):615-631. PubMed ID: 34903604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening of HELQ in breast and ovarian cancer families.
    Pelttari LM; Kinnunen L; Kiiski JI; Khan S; Blomqvist C; Aittomäki K; Nevanlinna H
    Fam Cancer; 2016 Jan; 15(1):19-23. PubMed ID: 26351136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
    Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
    Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
    Lu HM; Li S; Black MH; Lee S; Hoiness R; Wu S; Mu W; Huether R; Chen J; Sridhar S; Tian Y; McFarland R; Dolinsky J; Tippin Davis B; Mexal S; Dunlop C; Elliott A
    JAMA Oncol; 2019 Jan; 5(1):51-57. PubMed ID: 30128536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
    Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
    Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.